Annual CFO
-$12.85 M
+$4.75 M+26.99%
31 December 2023
Summary:
Salarius Pharmaceuticals annual cash flow from operations is currently -$12.85 million, with the most recent change of +$4.75 million (+26.99%) on 31 December 2023. During the last 3 years, it has fallen by -$2.53 million (-24.58%). SLRX annual CFO is now -25.94% below its all-time high of -$10.20 million, reached on 31 December 2021.SLRX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$1.36 M
-$284.50 K-26.53%
30 September 2024
Summary:
Salarius Pharmaceuticals quarterly cash flow from operations is currently -$1.36 million, with the most recent change of -$284.50 thousand (-26.53%) on 30 September 2024. Over the past year, it has increased by +$2.39 million (+63.81%). SLRX quarterly CFO is now -82.60% below its all-time high of -$743.00 thousand, reached on 30 June 2019.SLRX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$5.29 M
+$2.39 M+31.12%
30 September 2024
Summary:
Salarius Pharmaceuticals TTM cash flow from operations is currently -$5.29 million, with the most recent change of +$2.39 million (+31.12%) on 30 September 2024. Over the past year, it has increased by +$10.75 million (+67.01%). SLRX TTM CFO is now -27.86% below its all-time high of -$4.14 million, reached on 31 March 2015.SLRX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SLRX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +27.0% | +63.8% | +67.0% |
| 3 y3 years | -24.6% | +14.2% | +40.2% |
| 5 y5 years | +45.6% | +75.5% | +56.2% |
SLRX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -25.9% | +27.0% | -26.5% | +76.4% | at high | +70.7% |
| 5 y | 5 years | -25.9% | +45.6% | -26.5% | +76.4% | at high | +70.7% |
| alltime | all time | -25.9% | +59.9% | -82.6% | +85.6% | -27.9% | +83.5% |
Salarius Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$1.36 M(+26.5%) | -$5.29 M(-31.1%) |
| June 2024 | - | -$1.07 M(-20.8%) | -$7.69 M(-30.3%) |
| Mar 2024 | - | -$1.35 M(-10.4%) | -$11.03 M(-14.1%) |
| Dec 2023 | -$12.85 M(-27.0%) | -$1.51 M(-59.7%) | -$12.85 M(-20.0%) |
| Sept 2023 | - | -$3.75 M(-15.1%) | -$16.05 M(-11.0%) |
| June 2023 | - | -$4.42 M(+39.3%) | -$18.04 M(+4.6%) |
| Mar 2023 | - | -$3.17 M(-32.8%) | -$17.24 M(-2.0%) |
| Dec 2022 | -$17.60 M(+72.5%) | -$4.71 M(-17.9%) | -$17.60 M(+12.8%) |
| Sept 2022 | - | -$5.74 M(+58.6%) | -$15.60 M(+36.3%) |
| June 2022 | - | -$3.62 M(+2.8%) | -$11.44 M(+4.0%) |
| Mar 2022 | - | -$3.52 M(+29.4%) | -$11.00 M(+7.8%) |
| Dec 2021 | -$10.20 M(-1.1%) | -$2.72 M(+72.0%) | -$10.20 M(+15.2%) |
| Sept 2021 | - | -$1.58 M(-50.2%) | -$8.85 M(-11.7%) |
| June 2021 | - | -$3.17 M(+16.6%) | -$10.02 M(+7.5%) |
| Mar 2021 | - | -$2.72 M(+98.2%) | -$9.33 M(-9.6%) |
| Dec 2020 | -$10.31 M(-11.0%) | -$1.37 M(-50.1%) | -$10.31 M(-10.9%) |
| Sept 2020 | - | -$2.75 M(+11.2%) | -$11.57 M(-19.4%) |
| June 2020 | - | -$2.48 M(-33.2%) | -$14.36 M(+13.7%) |
| Mar 2020 | - | -$3.71 M(+40.6%) | -$12.63 M(+9.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | -$11.58 M(-50.9%) | -$2.64 M(-52.4%) | -$11.58 M(-4.1%) |
| Sept 2019 | - | -$5.54 M(+645.9%) | -$12.08 M(+29.4%) |
| June 2019 | - | -$743.00 K(-72.1%) | -$9.33 M(-44.6%) |
| Mar 2019 | - | -$2.66 M(-15.2%) | -$16.84 M(-28.6%) |
| Dec 2018 | -$23.60 M(-14.9%) | -$3.13 M(+12.1%) | -$23.60 M(-10.0%) |
| Sept 2018 | - | -$2.80 M(-66.1%) | -$26.22 M(-16.7%) |
| June 2018 | - | -$8.26 M(-12.3%) | -$31.47 M(+8.9%) |
| Mar 2018 | - | -$9.41 M(+63.5%) | -$28.91 M(+4.3%) |
| Dec 2017 | -$27.72 M(-13.5%) | -$5.76 M(-28.5%) | -$27.72 M(-1.9%) |
| Sept 2017 | - | -$8.05 M(+41.5%) | -$28.27 M(+2.9%) |
| June 2017 | - | -$5.69 M(-30.8%) | -$27.47 M(-11.7%) |
| Mar 2017 | - | -$8.23 M(+30.6%) | -$31.10 M(-3.0%) |
| Dec 2016 | -$32.05 M(+54.5%) | -$6.30 M(-13.1%) | -$32.05 M(+2.8%) |
| Sept 2016 | - | -$7.25 M(-22.3%) | -$31.19 M(+1.8%) |
| June 2016 | - | -$9.33 M(+1.7%) | -$30.64 M(+18.9%) |
| Mar 2016 | - | -$9.17 M(+68.7%) | -$25.78 M(+24.3%) |
| Dec 2015 | -$20.75 M | -$5.44 M(-18.9%) | -$20.75 M(+35.5%) |
| Sept 2015 | - | -$6.70 M(+50.1%) | -$15.31 M(+77.9%) |
| June 2015 | - | -$4.46 M(+7.8%) | -$8.61 M(+107.8%) |
| Mar 2015 | - | -$4.14 M | -$4.14 M |
FAQ
- What is Salarius Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Salarius Pharmaceuticals?
- What is Salarius Pharmaceuticals annual CFO year-on-year change?
- What is Salarius Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Salarius Pharmaceuticals?
- What is Salarius Pharmaceuticals quarterly CFO year-on-year change?
- What is Salarius Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Salarius Pharmaceuticals?
- What is Salarius Pharmaceuticals TTM CFO year-on-year change?
What is Salarius Pharmaceuticals annual cash flow from operations?
The current annual CFO of SLRX is -$12.85 M
What is the all time high annual CFO for Salarius Pharmaceuticals?
Salarius Pharmaceuticals all-time high annual cash flow from operations is -$10.20 M
What is Salarius Pharmaceuticals annual CFO year-on-year change?
Over the past year, SLRX annual cash flow from operations has changed by +$4.75 M (+26.99%)
What is Salarius Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of SLRX is -$1.36 M
What is the all time high quarterly CFO for Salarius Pharmaceuticals?
Salarius Pharmaceuticals all-time high quarterly cash flow from operations is -$743.00 K
What is Salarius Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, SLRX quarterly cash flow from operations has changed by +$2.39 M (+63.81%)
What is Salarius Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of SLRX is -$5.29 M
What is the all time high TTM CFO for Salarius Pharmaceuticals?
Salarius Pharmaceuticals all-time high TTM cash flow from operations is -$4.14 M
What is Salarius Pharmaceuticals TTM CFO year-on-year change?
Over the past year, SLRX TTM cash flow from operations has changed by +$10.75 M (+67.01%)